Concerns about cardiotoxicity in the HERA trial

Lancet. 2017 Dec 23;390(10114):2767. doi: 10.1016/S0140-6736(17)31954-2.

¹ Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France; Faculté de Médecine, Université Paris-Saclay, Kremlin Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: antonin.levy@gustaveroussy.fr.
² Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France; Faculté de Médecine, Université Paris-Saclay, Kremlin Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France; Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.
³ Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France; Faculté de Médecine, Université Paris-Saclay, Kremlin Bicêtre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France.

No abstract available

Publication types